Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

More articles from Current Drug Therapy

  • You have access
    Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
    Vania Modesto-Lowe, MD, MPH, Margaret M. Chaplin, MD, Roberto León-Barriera, MD and Lakshit Jain, MD
    Cleveland Clinic Journal of Medicine May 2024, 91 (5) 293-299; DOI: https://doi.org/10.3949/ccjm.91a.23061

    The authors review measures for preventing harm before benzodiazepines are prescribed, decreasing harm within 4 weeks after they are prescribed, and limiting harmful effects of long-term prescribing.

  • You have access
    Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
    Abhayjit Singh, MD and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058

    Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

  • You have access
    A practical guide for buprenorphine initiation in the primary care setting
    Roberto León-Barriera, MD, Samantha Jayne Zwiebel, MD, MA and Vania Modesto-Lowe, MD, MPH
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 557-564; DOI: https://doi.org/10.3949/ccjm.90a.23022

    The authors review changes in prescribing laws and outline buprenorphine induction protocols that can be adopted in the primary care setting.

  • Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
    You have access
    Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
    Alexa Nicole Fiffick, DO, MBS, NCMP, Tara K. Iyer, MD, NCMP, Tiffany Cochran, MD, MA, NCMP and Pelin Batur, MD, FACP, NCMP
    Cleveland Clinic Journal of Medicine March 2023, 90 (3) 181-190; DOI: https://doi.org/10.3949/ccjm.90a.22075

    Rates of unintended pregnancy are high in the United States. Clinicians need to be well-informed about the full spectrum of contraceptive options to improve reproductive autonomy.

  • You have access
    Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • You have access
    The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

  • You have access
    Prescribing testosterone and DHEA: The role of androgens in women
    Taryn Smith, MD, NCMP and Pelin Batur, MD, FACP, NCMP
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 35-43; DOI: https://doi.org/10.3949/ccjm.88a.20030

    Androgens play an important physiologic role and can promote sexual health.

  • You have access
    CGRP antagonists for decreasing migraine frequency: New options, long overdue
    Julia Bucklan, DO and Zubair Ahmed, MD
    Cleveland Clinic Journal of Medicine April 2020, 87 (4) 211-218; DOI: https://doi.org/10.3949/ccjm.87a.19048

    CGRP drugs are an exciting frontier, but migraine management is still a combination of lifestyle changes plus treatment.

  • You have access
    Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

  • You have access
    ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, MBCHB, MRCP (UK), Duha Ilyas, MBBS, MRCP (UK) and Sunil Bhandari, MBCHB, FRCP, PhD, M CLIN EDU, FHEA
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 601-607; DOI: https://doi.org/10.3949/ccjm.86a.18024

    Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire